Another research investigated how the gut microbiome affects clinical responses to anti-PD-1/PD-L1 immunotherapy (nivolumab, pembrolizumab, atezolizumab, and durvalumab) in gastrointestinal cancer patients, including CRC, esophageal cancer, and gastric cancer. This evidence concerns the gene CD274 and colorectal carcinoma.